AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10694141 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO (same dosage of maltodextrins)
Number of subjects: 17
Study 9546962 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded load treadmill protocol (3.2 km/h, 0% gradient increasing by 3.5% every 3 min)
Number of subjects: 14
Study 9546962 — intervention group
Group type: COMPARATOR
Intervention: Constant load treadmill protocol (3.2 km/h, 10% gradient)
Number of subjects: 14
Study 9546962 — intervention group
Group type: COMPARATOR
Intervention: Constant load treadmill protocol
Number of subjects: 14
Study 9546962 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded load treadmill protocol
Number of subjects: 14
Study 8201609 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 106
Study 8201609 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 106
Study 8201609 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (control)
Number of subjects: 106
Study 3204161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 10
Study 3204161 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment modalities)
Number of subjects: 10
Study 30575683 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath delta value (BDV) measurement every 4 hours for 7 days
Number of subjects: 20
Study 30575683 — intervention group
Group type: COMPARATOR
Intervention: Breath delta value (BDV) measurement
Number of subjects: 20
Study 30575683 — intervention group
Group type: EXPERIMENTAL
Intervention: BDV greater than 1.4‰
Number of subjects: 20
Study 28440034 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 20 min, anodal stimulation over M1 for 4 consecutive days)
Number of subjects: 50
Study 28440034 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 50
Study 28440034 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 50
Study 25716971 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 12 weeks
Number of subjects: 18
Study 22700526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) received a month of weekly 4-hour training for nursing home staff.
Number of subjects: 230
Study 22700526 — intervention group
Group type: COMPARATOR
Intervention: Reference Group (RG) did not receive the training.
Number of subjects: 230
Study 21381995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Team Care Arrangements (TCAs)
Number of subjects: 1752
Study 21381995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Assessment of Chronic Illness Care (PACIC) scores for patients with TCAs
Number of subjects: 1752
Study 21381995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TCA)
Number of subjects: 1752
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Text presentation format
Number of subjects: 0
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic presentation format
Number of subjects: 0
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of text and graphics presentation format
Number of subjects: 0
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comprehension
Number of subjects: 0
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculation and operations numeracy skill
Number of subjects: 0
Study 19919298 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy skill and income
Number of subjects: 0
Study 16500498 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity pattern assessed by transthoracic color Doppler echocardiography (TTCDE)
Number of subjects: 64
Study 10989321 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg/day)
Number of subjects: 19
Study 10989321 — intervention group
Group type: COMPARATOR
Intervention: Control (without doxazosin)
Number of subjects: 19
Study 9194510 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 24
Study 9194510 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of hydrochlorothiazide and amiloride
Number of subjects: 24
Study 9194510 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine and combined diuretics
Number of subjects: 24
Study 9194510 — intervention group
Group type: COMPARATOR
Intervention: alpha-methyldopa and combination of hydrochlorothiazide and amiloride
Number of subjects: 24
Study 8363072 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 120
Study 8363072 — intervention group
Group type: COMPARATOR
Intervention: 1 mg morphine in saline
Number of subjects: 120
Study 8363072 — intervention group
Group type: COMPARATOR
Intervention: 2 mg morphine in saline
Number of subjects: 120
Study 8363072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine in 0.25% bupivacaine
Number of subjects: 120
Study 3929694 — intervention group
Group type: EXPERIMENTAL
Intervention: FT + PSK
Number of subjects: 3630
Study 3929694 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK, MMC and FT combination
Number of subjects: 3630
Study 3929694 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK, OK, MMC and FT
Number of subjects: 3630
Study 3929694 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK administration
Number of subjects: 3630
Study 3929694 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK and/or OK with MMC and FT
Number of subjects: 3630
Study 29650130 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session group mantra-meditation for 20 minutes
Number of subjects: 30
Study 29650130 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session group mantra-meditation
Number of subjects: 30
Study 29650130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meditation)
Number of subjects: 30
Study 25582434 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks (COMP) worn during exercise
Number of subjects: 10
Study 25582434 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) with no compression socks worn
Number of subjects: 10
Study 23914814 — intervention group
Group type: EXPERIMENTAL
Intervention: Death prime
Number of subjects: 377
Study 23914814 — intervention group
Group type: COMPARATOR
Intervention: Pain prime (control)
Number of subjects: 377
Study 22823253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh breastmilk
Number of subjects: 18
Study 22823253 — intervention group
Group type: COMPARATOR
Intervention: Thawed breastmilk
Number of subjects: 18
Study 21401248 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 355
Study 21401248 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message
Number of subjects: 355
Study 18182964 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 122
Study 18182964 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 122
Study 18182964 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and Methylphenidate
Number of subjects: 122
Study 18182964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 16645424 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Mg-citrate (42 mEq K/d and 21 mEq Mg/d)
Number of subjects: 22
Study 16645424 — intervention group
Group type: COMPARATOR
Intervention: KCl (42 mEq/d)
Number of subjects: 22
Study 16645424 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Mg-citrate
Number of subjects: 22
Study 16645424 — intervention group
Group type: COMPARATOR
Intervention: KCl
Number of subjects: 22
Study 12870137 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly chest radiographs to detect second primaries
Number of subjects: 0
Study 12870137 — intervention group
Group type: COMPARATOR
Intervention: Routine use of computed axial tomography (CAT) scans, bone scans, brain imaging, and serum tumor markers
Number of subjects: 0
Study 12870137 — intervention group
Group type: COMPARATOR
Intervention: Adherence to breast cancer follow-up clinical practice guidelines
Number of subjects: 0
Study 10816061 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 19
Study 8727400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping forward in response to backward surface translation with predictable perturbation velocities (blocked order)
Number of subjects: 11
Study 8727400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping forward in response to backward surface translation with unpredictable perturbation velocities (random order)
Number of subjects: 11
Study 8727400 — intervention group
Group type: COMPARATOR
Intervention: Maintaining stance during backward surface translation
Number of subjects: 11
Study 8727400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping forward in response to surface perturbation regardless of velocity presentation order
Number of subjects: 11
Study 1840065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 24
Study 1840065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 24
Study 1840065 — intervention group
Group type: COMPARATOR
Intervention: Conventional antidepressants
Number of subjects: 24
Study 6974303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpryn, capsules containing enteric‐coated pellets
Number of subjects: 11
Study 6974303 — intervention group
Group type: COMPARATOR
Intervention: Rhusal, an enteric‐coated tablet
Number of subjects: 11
Study 6974303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric‐coated pellet capsules
Number of subjects: 11
Study 31693540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 117
Study 31693540 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard condition)
Number of subjects: 117
Study 30692123 — intervention group
Group type: EXPERIMENTAL
Intervention: MAA868, single subcutaneous doses
Number of subjects: 0
Study 28883521 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity
Number of subjects: 48919
Study 25880636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent CVR use (to allow menstruation)
Number of subjects: 120
Study 25880636 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CVR use
Number of subjects: 120
Study 23929148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior nasal packing
Number of subjects: 73
Study 23929148 — intervention group
Group type: COMPARATOR
Intervention: No anterior nasal packing
Number of subjects: 73
Study 23929148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (packed and not packed)
Number of subjects: 73
Study 21545397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose valsartan (10/20 mg)
Number of subjects: 261
Study 21545397 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose valsartan (40/80 mg)
Number of subjects: 261
Study 21545397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose valsartan (80/160 mg)
Number of subjects: 261
Study 21545397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled valsartan group
Number of subjects: 261
Study 21545397 — intervention group
Group type: COMPARATOR
Intervention: Pooled placebo group
Number of subjects: 261
Study 17886168 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS on left DLPFC
Number of subjects: 54
Study 17886168 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS on right DLPFC
Number of subjects: 54
Study 17886168 — intervention group
Group type: COMPARATOR
Intervention: Sham HF-rTMS
Number of subjects: 54
Study 16871272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 0
Study 16871272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 0
Study 16871272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15104857 — intervention group
Group type: EXPERIMENTAL
Intervention: No noise and no interruption
Number of subjects: 48
Study 15104857 — intervention group
Group type: COMPARATOR
Intervention: Noise and interruption
Number of subjects: 48
Study 11353877 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril, 20 mg od)
Number of subjects: 58
Study 11353877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11353877 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 58
Study 9398953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional anaesthesia (IVRA)
Number of subjects: 121
Study 9398953 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 121
Study 8184233 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-filled balls (Pezziballs)
Number of subjects: 46
Study 8184233 — intervention group
Group type: COMPARATOR
Intervention: Conventional seating
Number of subjects: 46
Study 3310158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 10 mg
Number of subjects: 7
Study 3310158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 5 mg
Number of subjects: 7
Study 3310158 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study 29283679 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens (treatment)
Number of subjects: 16
Study 29283679 — intervention group
Group type: COMPARATOR
Intervention: Conventional rigid gas permeable lens (control)
Number of subjects: 16
Study 29283679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both eyes (treatment and control)
Number of subjects: 16
Study 27253993 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during CPR
Number of subjects: 75
Study 25709399 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3199 via a Spira nebulizer (Turbuhaler; equivalent delivered doses 5‐3200 μg) or Turbuhaler (single delivered doses of 120‐1920 μg or repeated delivered once‐daily doses 240‐1,680 μg)
Number of subjects: 0
Study 23926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypobaric hypoxia (10,000 m altitude)
Number of subjects: 28
Study 23926651 — intervention group
Group type: COMPARATOR
Intervention: Control group (sea level)
Number of subjects: 28
Study 20876601 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-tip catheter
Number of subjects: 463
Study 20876601 — intervention group
Group type: COMPARATOR
Intervention: Control catheter
Number of subjects: 463
Study 18676275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative regional intra-arterial chemotherapy (PRAC)
Number of subjects: 45
Study 18676275 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection only
Number of subjects: 45
Study 16169761 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Formoterol 9 microg bid
Number of subjects: 38
Study 16169761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 12648711 — intervention group
Group type: COMPARATOR
Intervention: Fotemustine alone (arm A)
Number of subjects: 76
Study 12648711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotemustine plus whole brain irradiation (arm B)
Number of subjects: 76
Study 10714479 — intervention group
Group type: EXPERIMENTAL
Intervention: High respirable dose formulation at 30 l min(‐1)
Number of subjects: 24
Study 10714479 — intervention group
Group type: EXPERIMENTAL
Intervention: High respirable dose formulation at 60 l min(‐1)
Number of subjects: 24
Study 10714479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low respirable dose formulation at 30 l min(‐1)
Number of subjects: 24
Study 10714479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low respirable dose formulation at 60 l min(‐1)
Number of subjects: 24
Study 10714479 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urinary excretion between formulations
Number of subjects: 24
Study 8774398 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose subcutaneous heparin (12,500 units twice per day)
Number of subjects: 984
Study 8774398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose subcutaneous heparin (5000 units twice per day)
Number of subjects: 984
Study 8774398 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 984
Study 8774398 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 984
Study 8774398 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 984
Study 1282178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 or 20 mg b.i.d.)
Number of subjects: 77
Study 1282178 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 or 80 mg t.i.d.)
Number of subjects: 77
Study 6380286 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging by laparotomy (Group I)
Number of subjects: 104
Study 6380286 — intervention group
Group type: COMPARATOR
Intervention: Staging by closed techniques (Group II)
Number of subjects: 104
Study 31004969 — intervention group
Group type: EXPERIMENTAL
Intervention: Free from Falls Online (FFFO) - eight weekly sessions with instructional and exercise components
Number of subjects: 30
Study 31004969 — intervention group
Group type: COMPARATOR
Intervention: Control group - received a brochure on minimizing fall risk and a letter to their treating physician
Number of subjects: 30
Study 31004969 — intervention group
Group type: EXPERIMENTAL
Intervention: Free from Falls Online (FFFO)
Number of subjects: 30
Study 28662279 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐MPA
Number of subjects: 24
Study 28662279 — intervention group
Group type: COMPARATOR
Intervention: CsA‐MPA
Number of subjects: 24
Study 26031820 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative intervention for acute cholecystitis
Number of subjects: 1399
Study 26031820 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment for acute cholecystitis
Number of subjects: 1399
Study 24164228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (InGaAlP laser)
Number of subjects: 60
Study 24164228 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 60
Study 20390249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-midvastus (MMV) approach
Number of subjects: 30
Study 20390249 — intervention group
Group type: COMPARATOR
Intervention: Limited medial parapatellar (LMPP) approach
Number of subjects: 30
Study 19567213 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 19567213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19567213 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 17024797 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin (100 mg vaginal ovules for 6 days)
Number of subjects: 81
Study 17024797 — intervention group
Group type: COMPARATOR
Intervention: Meclocycline (35 mg vaginal ovules for 6 days)
Number of subjects: 81
Study 12835609 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Computer-assisted Self-interviewing
Number of subjects: 69
Study 10685667 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 281
Study 10685667 — intervention group
Group type: COMPARATOR
Intervention: IL-2 and IFN-alpha combination
Number of subjects: 281
Study 10685667 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha alone
Number of subjects: 281
Study 10685667 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 281
Study 8775698 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physical therapy plus continuous passive motion (CPM)
Number of subjects: 26
Study 8775698 — intervention group
Group type: COMPARATOR
Intervention: Postoperative physical therapy (Control)
Number of subjects: 26
Study 1289413 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c.t.i.w.
Number of subjects: 87
Study 1289413 — intervention group
Group type: COMPARATOR
Intervention: IFN-beta ser, 180 million units t.i.w.
Number of subjects: 87
Study 1289413 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b
Number of subjects: 87
Study 1289413 — intervention group
Group type: COMPARATOR
Intervention: IFN-beta ser
Number of subjects: 87
Study 6150000 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 12
Study 6150000 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (2 mg)
Number of subjects: 12
Study 6150000 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 12
Study 6150000 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa
Number of subjects: 12
Study 6150000 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 12
Study 6150000 — intervention group
Group type: COMPARATOR
Intervention: RX 781094 (0.3 mg/kg)
Number of subjects: 12
Study 30230920 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIERPE (high-intensity interval exercise prescribed and self-regulated by RPE, 25 min)
Number of subjects: 11
Study 30230920 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIEHR (high-intensity interval exercise prescribed and regulated by HR response to CPX, 25 min)
Number of subjects: 11
Study 30230920 — intervention group
Group type: EXPERIMENTAL
Intervention: MICE (continuous moderate-intensity exercise, 30 min)
Number of subjects: 11
Study 30230920 — intervention group
Group type: COMPARATOR
Intervention: Control (30 min of seated resting)
Number of subjects: 11
Study 30394151 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (5-hour training for GPs)
Number of subjects: 640
Study 26851191 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention group (disclosure of FTO risk)
Number of subjects: 1279
Study 26851191 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention group (encouraged to increase PA)
Number of subjects: 1279
Study 26851191 — intervention group
Group type: COMPARATOR
Intervention: Nonrisk participants (disclosure of genotype)
Number of subjects: 1279
Study 26851191 — intervention group
Group type: COMPARATOR
Intervention: Baseline PA measurement
Number of subjects: 1279
Study 24532078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/die for 2 days)
Number of subjects: 11
Study 24532078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24532078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 11
Study 21075465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 577